Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rollover study of nedosiran in primary hyperoxaluria
2024-512260-54-00Phase 3Authorised
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Aug 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Annual rate of decline in eGFR in participants with PH1. Planned start Aug 2019; status: authorised.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on 2024-512260-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512260-54-00.